Clinical and biochemical aspects of primary and secondary hyperammonemic disorders

被引:98
作者
Haeberle, Johannes [1 ]
机构
[1] Univ Childrens Hosp Zurich, Div Metab, CH-8032 Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
Hyperammonemia; Urea cycle disorders; Organic acidemias; Glutamine synthetase; N-acetylglutamate synthase; Hyperammonemic coma; UREA CYCLE DISORDERS; LYSINURIC PROTEIN INTOLERANCE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACID HEPATIC FATALITIES; GLUTAMINE-SYNTHETASE; SYNTHASE DEFICIENCY; N-ACETYLGLUTAMATE; INBORN ERROR; COENZYME-A; FUNCTIONAL-CHARACTERIZATION;
D O I
10.1016/j.abb.2013.04.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An increased concentration of ammonia is a non-specific laboratory sign indicating the presence of potentially toxic free ammonia that is not normally removed. This does occur in many different conditions for which hyperammonemia is a surrogate marker. Hyperammonemia can occur due to increased production or impaired detoxification of ammonia and should, if associated with clinical symptoms, be regarded as an emergency. The conditions can be classified into primary or secondary hyperammonemias depending on the underlying pathophysiology. If the urea cycle is directly affected by a defect of any of the involved enzymes or transporters, this results in primary hyperammonemia. If however the function of the urea cycle is inhibited by toxic metabolites or by substrate deficiencies, the situation is described as secondary hyperammonemia. For removal of ammonia, mammals require the action of glutamine synthetase in addition to the urea cycle, in order to ensure lowering of plasma ammonia concentrations to the normal range. Independent of its etiology, hyperammonemia may result in irreversible brain damage if not treated early and thoroughly. Thus, early recognition of a hyperammonemic state and immediate initiation of the specific management are of utmost importance. The main prognostic factors are, irrespective of the underlying cause, the duration of the hyperammonemic coma and the extent of ammonia accumulation. This paper will discuss the biochemical background of primary and secondary hyperammonemia and will give an overview of the various underlying conditions including a brief clinical outline and information on the genetic backgrounds. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 139 条
  • [1] Ammonium metabolism in humans
    Adeva, Maria M.
    Souto, Gema
    Blanco, Natalia
    Donapetry, Cristobal
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (11): : 1495 - 1511
  • [2] New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA
    Aires, Catia C. P.
    van Cruchten, Arno
    Ijlst, Lodewijk
    de Almeida, Isabel Tavares
    Duran, Marinus
    Wanders, Ronald J. A.
    Silva, Margarida F. B.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (02) : 426 - 434
  • [3] Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome
    Albrecht, J
    Jones, EA
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 170 (02) : 138 - 146
  • [4] Long-term outcome of patients with urea cycle disorders and the question of neonatal screening
    Bachmann, C
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2003, 162 (Suppl 1) : S29 - S33
  • [5] Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation
    Bachmann, C
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2003, 162 (06) : 410 - 416
  • [6] Mechanisms of hyperammonemia
    Bachmann, C
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (07) : 653 - 662
  • [7] Bachmann C, 2006, PATHOPHYSIOLOGY MANA, P157
  • [8] Bachmann C, 2003, PHYS GUIDE LAB DIAGN, P261
  • [9] TRANSIENT HYPER-AMMONEMIA OF PRETERM INFANT
    BALLARD, RA
    VINOCUR, B
    REYNOLDS, JW
    WENNBERG, RP
    MERRITT, A
    SWEETMAN, L
    NYHAN, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1978, 299 (17) : 920 - 925
  • [10] Hyperammonemia with reduced ornithine, citrulline, arginine and proline:: a new inborn error caused by a mutation in the gene encoding Δ1-pyrroline-5-carboxylate synthase
    Baumgartner, MR
    Hu, CAA
    Almashanu, S
    Steel, G
    Obie, C
    Aral, B
    Rabier, D
    Kamoun, P
    Saudubray, JM
    Valle, D
    [J]. HUMAN MOLECULAR GENETICS, 2000, 9 (19) : 2853 - 2858